Brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report $24.81 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Acorda Therapeutics’ earnings, with estimates ranging from $7.80 million to $39.70 million. Acorda Therapeutics posted sales of $153.30 million during the same quarter last year, which suggests a […]
Read More
